June 2, 2023
Eisai Co., Ltd.

No.23-40

EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 37TH
ANNUAL SLEEP 2023 MEETING
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today a total of eight poster
presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant(product name: DAYVIGO®), will be given at the 37th annual meeting of the Associated Professional Sleep
Societies (SLEEP 2023), to be held from June 3 to 7, 2023 in Indianapolis, IN, the United States.
Major poster presentations include new data about the effects of lemborexant on obstructive sleep apnea(poster numbers: #298, 299 and 300).
Eisai considers neurology, including insomnia, a therapeutic area of focus. Eisai strives to create innovative
products as soon as possible in therapeutic areas with high unmet medical needs, and will further contributeto addressing the diverse needs of, as well as increasing the benefits provided to, those living withneurological diseases and their families.

SLEEP 2023 Poster Presentations
Asset and Presentation Details(Time EDT)
Lemborexant
Poster #297
Monday, June 5, 12:00 - 13:15
Lemborexant
Poster #298
Monday, June 5, 17:00 – 18:00
Lemborexant
Poster #299
Monday, June 5, 12:00 - 13:15
Lemborexant
Poster #300
Monday, June 5, 17:00 – 18:00
Lemborexant
Poster #301
Monday, June 5, 12:00 - 13:15
Lemborexant
Poster #302
Monday, June 5, 17:00 – 18:00
Lemborexant
Poster #303
Monday, June 5, 12:00 – 13:15

Title
Long-term Efficacy of Lemborexant on Objective Sleep
Measures in Clinical Practice
Effect of Lemborexant on Sleep Architecture in Subjects
with Comorbid Insomnia and Mild Obstructive Sleep Apnea
from a Ph 3 TrialThe Effect of Lemborexant on Polysomnographic Sleep
Parameters in Adults with Mild, Moderate, or Severe
Obstructive Sleep Apnea
Effect of Lemborexant on Sleep Architecture in Adult andElderly Subjects with Mild to Severe Obstructive Sleep
Apnea
Shifts in Daytime Functioning Items on the Insomnia
Severity Scale with Lemborexant after 6 Months ofTreatment
Differential Effect of Lemborexant and Zolpidem on Wake
Across the Night in Patients with Insomnia Disorder
Impact of Lemborexant on Daytime Ratings ofSleepiness/Alertness in Subjects with Insomnia Disorderand Baseline SleepinessNarcolepsy general
Poster #248
Monday, June 5, 17:00 – 18:00

Burden of Narcolepsy in Japan: A Nationwide Real-world
Database Study from The Perspectives of Direct Medical
Cost and Comorbidity

Media Inquiries
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Eisai Inc. (U.S.)
TEL: +551-305-0050
Christopher_Vancheri@eisai.com[Notes to editors]
1. About Lemborexant (product name: DAYVIGO)
Lemborexant, an orexin receptor antagonist, is Eisai’s in-house discovered and developed small moleculethat inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors(orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence
lemborexant’s potential to facilitate improvements in sleep onset and maintenance with minimal morning
residual effects. It has been approved for the treatment of insomnia in over 15 countries including Japan,
the United States, Canada, Australia and countries in Asia.